Depomed and Esprit Announce Availability of ProQuin(R)XR 3-Tablet Blister Packs.MENLO PARK, Calif. & EAST BRUNSWICK, N.J. -- Depomed, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DEPO DEPO Delegated Episcopal Pastoral Oversight DEPO Devils Postpile National Monument (US National Park Service) DEPO Defence Export Promotion Organization (Pakistan) DEPO Double Even Pass Odd ) and Esprit Pharma, Inc. announced today that Once-Daily ProQuin(R)XR, the new, prolonged release once-daily formulation of ciprofloxacin hydrochloride ciprofloxacin hydrochloride Ciloxam, Cipro, Cipro I.V., Cipro XR, Ciproxin (UK) Pharmacologic class: Fluoroquinolone Therapeutic class: Anti-infective Pregnancy risk category C for the treatment of uncomplicated urinary tract infections (uUTI), is now available in 3-tablet blister packs, in addition to the original launch packaging of a bottle of 50 tablets. Esprit's 190-person sales and managed care organization are actively calling on physician offices and retail pharmacies nationwide."We are pleased to be able to offer physicians and pharmacies packaging options that will address the type and volume of prescriptions they are managing," said John Spitznagel, chairman and chief executive officer of Esprit. "For the high volume ProQuin XR users, the 50-count bottle remains available. The recent launch of the 3-tablet blister pack will provide a convenient alternative for patients when physicians prescribe three tablets, one per day, for the treatment of uUTI infections." John W. Fara, Ph.D., chairman, president and chief executive officer of Depomed, added, "I am pleased from a manufacturing perspective that we were able to respond quickly to the request from the marketplace for variations in ProQuin XR packaging. We believe the new ProQuin XR 3-tablet blister pack will help Esprit further penetrate the urology, women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. and key primary care physician markets." In July 2005, Depomed and Esprit entered into a commercialization agreement for ProQuin XR. Esprit launched ProQuin XR in the U.S. urology market in the fourth quarter 2005, and has subsequently launched the product into other attractive physician markets including women's health and key primary care markets. Depomed retains manufacturing rights and Esprit is responsible for sales, marketing and distribution. About ProQuin(R) XR ProQuin(R)XR is a once-daily prolonged-release formulation of ciprofloxacin hydrochloride approved to treat uncomplicated urinary tract infections (UTIs). UTIs are bacterial infections frequently caused by E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. and are typically treated with antibiotics. Patients should not take ProQuin(R)XR if they are allergic to, or have ever had a severe reaction to, ciprofloxacin ciprofloxacin /cip·ro·flox·a·cin/ (sip?ro-flok´sah-sin) a synthetic antibacterial effective against many gram-positive and gram-negative bacteria; used as the hydrochloride salt. cip·ro·flox·a·cin n. or to any other "quinolone" antibiotics. ProQuin(R)XR is generally well tolerated. The most common side effects with ProQuin(R)XR include vaginal yeast infection Vaginal yeast infection An overgrowth of fungus in the vaginal area. Mentioned in: Jock Itch and headache. ProQuin XR is available in 50-count bottles (NDC NDC National Drug Code NDC NATO Defense College NDC National Documentation Centre (National Hellenic Research Foundation, Athens, Greece) NDC National Dairy Council NDC National Democratic Congress : 13913-001-50) and 3-count blister packs (NDC: 15456-001-03). Pharmacy ordering information is available by emailing trade@espritpharma.com. To order product direct, please call (866) 377-7486. For more info please visit www.proquinxr.com. About Esprit Esprit Pharma is a niche oriented pharmaceutical company focused on specialty therapeutics to improve patient outcomes in the urology therapeutic area. Led by a strong and experienced management team, the Company focuses on exploring and identifying opportunities to selectively acquire and enhance the market potential of novel, commercially available therapeutics and late-stage development drugs addressing the needs of its market space. A privately held Company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , Esprit Pharma has investment support from the leading healthcare venture capital and private equity firms of Domain Associates, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control (http://www.domainvc.com/), New Enterprise Associates (http://www.nea.com/), and Apax Partners, Inc. (http://www.apax.com/). About Depomed Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm(TM) drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin(R) XR (ciprofloxacin hydrochloride) once daily, extended-release tablets have been approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the treatment of uncomplicated urinary tract infections. In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes Type II diabetes Type II diabetes is the most common form of diabetes and usually appears in middle aged adults. It is often associated with obesity and may be delayed or controlled with diet and exercise. Mentioned in: Diabetic Ketoacidosis have been approved in the U.S. and Canada. The company completed a Phase II trial in postherpetic neuralgia with its product, Gabapentin GR. Additional information about Depomed may be found at its web site, www.depomedinc.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our commercialization efforts and those of our collaborative partners, our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion